Immunotherapy and targeted therapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests an immunotherapy combination (iparomlimab and tuvonralimab) plus bevacizumab and chemotherapy as a first treatment for advanced colorectal cancer. The goal is to see if this combination can shrink tumors and help you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be advanced colorectal cancer that cannot be removed with surgery.
- You must not have received prior systemic treatment (except possibly some adjuvant chemotherapy that finished more than 6 months ago).
- Your tumor must be MSS or MSI-low (a specific genetic marker).
- You must have at least one measurable tumor (that can be tracked on scans) and be in generally good health (ECOG performance status 2 or better).
- You must not have active autoimmune disease, serious heart problems, uncontrolled infections, or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs and targeted radiation for people with advanced colorectal cancer that has spread to a few spots. It aims to see if this approach works better than the current standard treatment after other therapies have failed.
This study is testing a combination of drugs for colorectal cancer that has spread and hasn't responded to first-line treatment. It aims to see if these drugs can help control the cancer and improve outcomes for people in your situation.
This trial tests a combination of two medications, an immunotherapy (QL1706) and a blood-vessel-blocking drug (bevacizumab), for people with a type of colorectal cancer that has a specific genetic feature (MSI-H/dMMR). The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of radiation therapy with three drugs (an immunotherapy, a chemotherapy pill, and a targeted therapy) for advanced colorectal cancer. It aims to see if this combination can shrink tumors and improve outcomes for people whose cancer has not responded to standard treatments.
This trial tests a combination of chemotherapy, targeted therapy, and immunotherapy, with or without radiation to the primary tumor, for people with advanced rectal cancer that has a specific genetic profile. It aims to see if adding radiation improves outcomes.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.